Molecular mechanisms in the pathogenesis of diabetic nephropathy: An update

Vascular Pharmacology

Volumn 58, Issue 4, 2013, Pages 259-271

  Arora, Mandeep Kumar ^a   Singh, Umesh Kumar ^a  

^a SWAMI VIVEKANAND SUBHARTI UNIVERSITY   (India)

Author keywords

Diabetic nephropathy; Renal fibrosis; Signaling pathways; Target site

Indexed keywords

ADENOSINE; ALDOSTERONE; ALISKIREN; ANGIOTENSIN II; CANNABINOID RECEPTOR; JANUS KINASE; OSTEOPONTIN; PRORENIN RECEPTOR; PROTEIN KINASE C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN; RUBOXISTAURIN; STAT PROTEIN; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA;

DIABETIC NEPHROPATHY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY TUBULE NECROSIS; MICROALBUMINURIA; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; HYPERGLYCEMIA; SIGNAL TRANSDUCTION;

EID: 84875370568     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2013.01.001     Document Type: Review

References (196)

1. Aggarwal B.B. Signaling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 2003, 3:745-756.
2. Amann B., Tinzmann R., Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 2003, 26:2421-2425.
3. Amiri F., Shaw S., Wang X., Tang J., Waller J.L., Eaton D.C., Marrero M.B. Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int. 2002, 61:1605-1616.
4. Arora M.K., Reddy K., Balakumar P. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. Eur. J. Pharmacol. 2010, 636:137-144.
5. Asaba K., Tojo A., Onozato M.L., Goto A., Quinn M.T., Fujita T., Wilcox C.S. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int. 2005, 67:1890-1898.
6. Atfi A., Djelloul S., Chastre E., Davis R., Gespach C. Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor beta-mediated signaling. J. Biol. Chem. 1997, 272:1429-1432.
7. Awad A.S., Huang L., Ye H., Duong E.T., Bolton W.K., Linden J., Okusa M.D. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2006, 290:828-837.
8. Babazono T., Drezgic J.K., Dlugosz J.A., Whiteside C. Altered expression and subcellular localization of diacylglycerol-sensitive protein kinase C isoforms in diabetic rat glomerular cells. Diabetes 1998, 47:668-676.
9. Babior P.H. NADPH oxidase. Curr. Opin. Immunol. 2004, 16:42-47.
10. Barutta F., Corbelli A., Mastrocola R., Gambino R., Di Marzo V., Pinach S., Rastaldi M.P., Perin P.C., Gruden G. Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes 2010, 59:1046-1054.
11. Barutta F., Piscitelli F., Pinach S., Bruno G., Gambino R., Rastaldi M.P., Salvidio G., Di Marzo V., Cavallo, Perin P., Gruden G. Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes 2011, 60:2386-2396.
12. Baud L., Ardaillou R. Tumor necrosis factor in renal injury. Miner. Electrolyte Metab. 1995, 21:336-341.
13. Benigni A., Gagliardini E., Remuzzi G. Changes in glomerular perm-selectivity induced by angiotensin II imply podocyte dysfunction and slit diaphragm protein rearrangement. Semin. Nephrol. 2004, 24:131-140.
14. Berthier C.C., Zhang H., Schin M., Henger A., Nelson R.G., Yee B., Boucherot A., Neusser M.A., Cohen C.D., Carter-Su C., Argetsinger L.S., Rastaldi M.P., Brosius F.C., Kretzler M. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 2009, 58:469-477.
15. Brown N.J., Nakamura S., Ma L., Nakamura I., Donnert E., Freeman M., Vaughan D.E., Fogo A.B. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 2000, 58:1219-1227.
16. Cha D.R., Kim N.H., Yoon J.W., Jo S.K., Cho W.Y., Kim H.K., Won N.H. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int. Suppl. 2000, 58:104-112.
17. Cha D.R., Kang Y.S., Han S.Y., Jee Y.H., Han K.H., Han J.Y., Kim Y.S., Kim N.H. Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. J. Endocrinol. 2004, 183:183-194.
18. Cha D.R., Kang Y.S., Han S.Y., Jee Y.H., Han K.H., Kim H.K., et al. Role of aldosterone in diabetic nephropathy. Nephrol. Carlton. 2005, 10:37-39.
19. Chen Y.J., Quilley J. Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase expression and enhanced renal prostaglandin release. J. Phamacol. Exp. Therap. 2008, 324:658-663.
20. Chen L.L., Zhang J.Y., Wang B.P. Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1. Vasc. Pharmacol. 2006, 44:309-315.
21. Chen H., Huang X.R., Wang W., Li J., Heuchel R.L., Chung A.C., Lan H.Y. The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes 2010, 60:590-601.
22. Chin B.Y., Mohsenin A., Li S.X., Choi A.M., Choi M.E. Stimulation of pro-alpha (1) (I) collagen by TGF-beta(1) in mesangial cells: role of the p38 MAPK pathway. Am. J. Physiol. Renal Physiol. 2001, 280:495-504.
23. Choi M.E. Mechanism of transforming growth factor-b1 signaling: role of the mitogen-activated protein kinase. Kidney Int. 2000, 58:53-58.
24. Colucci M., Zoja C., Remuzzi G., Semeraro N. Reduced fibrinolytic activity in glomeruli isolated from rabbits infused with tumor necrosis factor. Haemostasis 1993, 23:173-178.
25. Cooper M.E., Vranes D., Youssef S., Stacker S.A., Cox A.J., Rizkalla B., Casley D.J., Bach L.A., Kelly D.J., Gilbert R.E. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999, 48:2229-2239.
26. Dalla-Vestra M., Saller A., Bortoloso E., Mauer M., Fioretto P. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab. 2000, 26:8-14.
27. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
28. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 1999, 20:649-688.
29. Deutsch D.G., Goligorsky M.S., Schmid P.C., Krebsbach R.J., Schmid H.H., Das S.K., Dey S.K., Arreaza G., Thorup C., Stefano G., Moore L.C. Production and physiological actions of anandamide in the vasculature of the rat kidney. J. Clin. Invest. 1997, 100:1538-1546.
30. Devaraj S., Tobias P., Jialal I. Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokine 2011, 55:441-445.
31. Dixon A.K., Gubitz A.K., Sirinathsinghji D.J., Richardson P.J., Freeman T.C. Tissue distribution of adenosine receptor mRNAs in the rat. Br. J. Pharmacol. 1996, 118:1461-1468.
32. Durvasula R.V., Petermann A.T., Hiromura K., Blonski M., Pippin J., Mundel P., Pichler R., Griffin S., Couser W.G., Shankland S.J. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 2004, 65:30-39.
33. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int. 1996, 49:578-597.
34. Etoh T., Inoguchi T., Kakimoto M., Sonoda N., Kobayashi K., Kuroda J., Sumimoto H., Nawata H. Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibility by interventive insulin treatment. Diabetologia 2003, 46:1428-1437.
35. Feldmann M., Brennan F.M., Maini R. Cytokines in autoimmune disorders. Int. Rev. Immunol. 1998, 17:217-228.
36. Feliers D., Gorin Y., Ghosh-Choudhury G., Abboud H.E., Kasinath B.S. Angiotensin II stimulation of VEGF mRNA translation requires production of reactive oxygen species. Am. J. Physiol. Renal Physiol. 2006, 290:927-936.
37. Flaquer M., Lloberas N., Franquesa M., Torras J., Vidal A., Rosa J.L., Herrero-Fresneda I., Grinyo J.M., Cruzado J.M. The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats. Life Sci. 2010, 87:147-153.
38. Franco M., Martinez F., Quiroz Y., Galicia O., Bautista R., Johnson R.J., Rodriguez-Iturbe B. Renal angiotensin II concentration and interstitial infiltration of immune cells are correlated with blood pressure levels in salt-sensitive hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293:251-256.
39. Fujihara C., Noronha I.L., Malheiros D.M.A., Antunes G.R., Oliveira I.B., Zatz R. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J. Am. Soc. Nephrol. 2000, 11:283-290.
40. Fujimoto M., Maezawa Y., Yokote K., Joh K., Kobayashi K., Kawamura H., Nishimura M., Roberts A.B., Saito Y., Mori S. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem. Biophys. Res. Commun. 2003, 305:1002-1007.
41. Fujisawa G., Okada K., Muto S., Fujita N., Itabashi N., Kusano E., Ishibashi S. Spironolactone prevents early renal injury in streptozotocin induced diabetic rats. Kidney Int. 2004, 66:1493-1502.
42. Fujita H., Fujishima H., Takahashi K., Sato T., Shimizu T., Morii T., Shimizu T., Shirasawa T., Qi Z., Breyer M.D., Harris R.C., Yamada Y., Takahashi T. SOD1, but not SOD3, deficiency accelerates diabetic renal injury in C57BL/6-Ins2(Akita) diabetic mice. Metabolism 2012, 10.1016/j.metabol.2012.05.005.
43. Fukasawa H., Yamamoto T., Suzuki H., Togawa A., Ohashi N., Fujigaki Y., Uchida C., Aoki M., Hosono M., Kitagawa M., Hishida A. Treatment with anti-TGF-beta antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-beta signaling. Kidney Int. 2004, 65:63-74.
44. Geiszt M., Kopp J.B., Varnai P., Leto T.L. Identification of renox, an NAD(P)H oxidase in kidney. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:8010-8014.
45. Giacchetti G., Sechi L.A., Rilli S., Carey R.M. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol. Metabol. 2005, 16:120-126.
46. Gill P.S., Wilcox C.S. NADPH oxidases in the kidney. Antioxid. Redox Signal. 2006, 8:1597-1607.
47. Gorin Y., Ricono J.M., Kim N.H., Bhandari B., Choudhury G.G., Abboud H.E. Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells. Am. J. Physiol. Renal Physiol. 2003, 285:219-229.
48. Gorin Y., Ricono J.M., Wagner B., Kim N.H., Bhandari B., Choudhury G.G., Abboud H.E. Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells. Biochem. J. 2004, 381:231-239.
49. Gorin Y., Block K., Hernandez J., Bhandari B., Wagner B., Barnes J.L., Abboud H.E. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J. Biol. Chem. 2005, 280:39616-39626.
50. Graciano M.L., Cavaglieri R.C., Delle H., Dominguez W.V., Casarini D.E., Malheiros D.M., Noronha I.L. Intrarenal renin-angiotensin system is unregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J. Am. Soc. Nephrol. 2004, 15:1805-1815.
51. Granger J.P., Schnackenberg C.G. Renal mechanisms of angiotensin II-induced hypertension. Semin. Nephrol. 2000, 20:417-425.
52. Graycar J.L., Miller D.A., Arrick B.A., Lyons R.M., Moses H.L., Derynck R. Human transforming growth factor-beta 3: recombinant expression, purification, and biological activities in comparison with transforming growth factors-beta 1 and -beta 2. Mol. Endocrinol. 1989, 3:1977-1986.
53. Guan Y., Breyer M.D. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 2001, 60:14-30.
54. Guo C., Martinez-Vasquez D., Mendez G.P., Toniolo M.F., Yao T.M., Oestreicher E.M., Kikuchi T., Lapointe N., Pojoga L., Williams G.H., Ricchiuti V., Adler G.K. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1, and 2 diabetes mellitus. Endocrinology 2006, 147:5363-5373.
55. Ha H., Lee H.B. Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int. Suppl. 2000, 77:19-25.
56. Han K.H., Kang Y.S., Han S.Y., Jee Y.H., Lee M.H., Han J.Y., Kim H.K., Kim Y.S., Cha D.R. Spironolactone ameliorates renal injury, and connective tissue growth factor expression in type II diabetic rats. Kidney Int. 2006, 70:111-120.
57. Han S.Y., Kim C.H., Kim H.S., Jee Y.H., Song H.K., Lee M.H., Han K.H., Kim H.K., Kang Y.S., Han J.Y., Kim Y.S., Cha D.R. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J. Am. Soc. Nephrol. 2006, 17:1362-1372.
58. Haneda M., Hoya D., Isono M., Kikkawa R. Overview of glucose signaling in mesangial cells in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14:1374-1382.
59. Hasegawa G., Nakano K., Sawada M., Uno K., Shibayama Y., Ienaga K., Kondo M. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int. 1991, 40:1007-1012.
60. Hayashida T., Schnaper H.W. High ambient glucose enhances sensitivity to TGF-β1 via extracellular signal-regulated kinase and protein kinase Cδ activities in human mesangial cells. J. Am. Soc. Nephrol. 2004, 15:2032-2041.
61. Hehlgans T., Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005, 115:1-20.
62. Hill C., Flyvbjerg A., Gronbaek H., Petrik J., Hill D.J., Thomas C.R., Sheppard M.C., Logan A. The expression of transforming growth factor beta (TGF- β) isoforms and their receptors in acute and chronic experimental diabetic nephropathy. Endocrinology 2000, 141:1196-1208.
63. Hill C., Flyvbjerg A., Rasch R., Bak M., Logan A. Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J. Endocrinol. 2001, 170:647-651.
64. Huang J.S., Guh J.Y., Hung W.C., Yang M.L., Lai Y.H., Chen H.C., Chuang L.Y. Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells. Biochem. J. 1999, 342:231-238.
65. Huang Y., Wongamorntham S., Kasting J., McQuillan D., Owens R.T., Yu L., Noble N.A., Border W. Renin increases mesangial cell transforming growth factor-bold italic beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006, 69:105-113.
66. Huhtala P.L.T.C., Tryggvason K. Structure of the human type IV collagen gene. J. Biol. Chem. 1990, 265:11077-11082.
67. Huwiler A., Ren S., Holthofer H., Pavenstadt H., Pfeilschifter J. Inflammatory cytokines upregulate nephrin expression in human embryonic kidney epithelial cells and podocytes. Biochem. Biophys. Res. Commun. 2003, 305:136-142.
68. Inoki K., Haneda M., Ishida T., Mori H., Maeda S., Koya D., Sugimoto T., Kikkawa R. Role of mitogen-activated protein kinases as downstream effectors of transforming growth factor-β in mesangial cells. Kidney Int. 2000, 58:76-80.
69. Irita J., Okura T., Jotoku M., Nagao T., Enomoto D., Kurata M., Desilva V.R., Miyoshi K., Matsui Y., Uede T., Denhardt D.T., Rittiling S.R., Higaki J. Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney. Am. J. Physiol. Ren. Physiol. 2011, 301:833-844.
70. Isono M., Chen S., Hong S.W., Iglesias-de la Cruz M.C., Ziyadeh F.N. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells. Biochem. Biophys. Res. Commun. 2002, 296:1356-1365.
71. Iwano M., Kubo A., Nishino T., Sato H., Nishioka H., Akai Y., Kurioka H., Fujii Y., Kanauchi M., Shiiki H., Dohi K. Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus. Kidney Int. 1996, 49:1120-1126.
72. Janiak P., Poirier B., Bidouard J.P., Cadrouvele C., Pierre F., Gouraud L., Barbosa I., Dedio J., Maffrand J.P., Le-Fur G., O'Connor S., Herbert J.M. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int. 2007, 72:1345-1357.
73. Jones S.A., Hancock J.T., Jones O.T., Neubauer A., Topley N. The expression of NADPH oxidase components in human glomerular mesangial cells: detection of protein and mRNA for p47phox, p67phox, and p22phox. J. Am. Soc. Nephrol. 1995, 5:1483-1491.
74. Junaid A., Hostetter T.H., Rosenberg M.E. Interaction of angiotensin II and TGF-β1 in the rat remnant kidney. J. Am. Soc. Nephrol. 1997, 8:1732-1738.
75. Kagami S., Border W.A., Miller D.E., Noble N.A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J. Clin. Invest. 1994, 93:2431-2437.
76. Kagami S., Kuhara T., Okada K., Kuroda Y., Border W.A., Noble N.A. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int. 1997, 51:664-671.
77. Kalantarinia K., Awad A.S., Siragy H.M. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 2003, 64:1208-1213.
78. Kang Y.S., Park Y.G., Kim B.K., Han S.Y., Jee Y.H., Han K.H., Lee M.H., Song H.K., Cha D.R., Kang S.W., Han D.S. Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J. Mol. Endocrinol. 2006, 36:377-388.
79. Kang Y.S., Lee M.H., Song H.K., Hyun Y.Y., Cha J.J., Ko G.J., Kim S.H., Lee J.E., Han J.Y., Cha D.R. Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Nephrol. Dial. Transplant. 2011, 26:1194-1204.
80. Kariya K., Kawahara Y., Tsuda T., Fukuzaki H., Takai Y. Possible involvement of protein kinase C in platelet-derived growth factor-stimulated DNA synthesis in vasucular smooth muscle cells. Atherosclerosis 1987, 63:251-255.
81. Kato S., Luyckx V.A., Ots M., Lee K.W., Ziai F., Troy J.L., Brenner B.M., MacKenzie H.S. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int. 1999, 56:1037-1048.
82. Kitada M., Koya D., Sugimoto T., Isono M., Araki S., Kashiwagi A., Haneda M. Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003, 52:2603-2614.
83. Ko G.J., Kang Y.S., Han S.Y., Lee M.H., Sang H.K., Han K.H. Pioglitazone attenuates diabetic nephropathy through an antiinflammatory mechanism in type 2 diabetic rats. Nephrol. Dil. Trans. 2008, 23:2750-2760.
84. Koya D., Jirousek M.R., Lin Y.W., Ishii H., Kuboki K., King G.L. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-β, extracellular matrix components and prostanoids in the glomeruli of diabetic rats. J. Clin. Invest. 1997, 100:115-126.
85. Koya D., Haneda M., Nakagawa H., Isshiki K., Sato H., Maeda S., Sugimoto T., Yasuda H., Kashiwagi A., Ways D.K., King G.L., Kikkawa R. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. Fed. Am. Soc. Exp. Biol. J. 2000, 14:439-447.
86. Kutz S.M., Hordines J., McKeown-Longo P.J., Higgins P.J. TGF-b1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. J. Cell Sci. 2001, 114:3905-3914.
87. Kuwabara T., Mori K., Mukoyama M., Kasahara M., Yokoi H., Saito Y., Ogawa Y., Imamaki H., Kawanishi T., Ishii A., Koga K., Mori K.P., Kato Y., Sugawara A., Nakao K. Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by toll-like receptor 4 in mice. Diabetologia 2012, 10.1007/s00125-012-2578-1.
88. Lai L.Y., Gu Y., Chen J., Yu S.Q., Ma J., Yang H.C., Lin S.Y. Production of aldosterone by rat mesangial cell, and the accumulation of extracellular matrix induced by aldosterone. Natl. Med. J. Chin. 2004, 83:1900-1905.
89. Lan H.Y., Chung A.C. Transforming growth factor-β and Smads. Contrib. Nephrol. 2011, 170:75-82.
90. Langham R.G., Kelly D.J., Gow R.M., Zhang Y., Dowling J.K., Thomson N.M., Gilbert R.E. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am. J. Kidney Dis. 2004, 44:826-831.
91. Lee H.B., Yu M.R., Yang Y., Jiang Z., Ha H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14:241-245.
92. Lee S.H., Yoo T.H., Nam B.Y., Kim D.K., Li J.J., Jung D.S., Kwak S.J., Ryu D.R., Han S.H., Lee J.E., Moon S.J., Han D.S., Kang S.W. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am. J. Physiol. Renal Physiol. 2009, 297:1381-1390.
93. Leehey D.J., Singh A.K., Alavi N., Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int. 2000, 58:S93-S98.
94. Li J.M., Shah A.M. ROS Generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14:221-226.
95. Li J.H., Huang X.R., Zhu H.J., Oldfield M., Cooper M., Truong L.D., Johnson R.J., Lan H.Y. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J. 2004, 18:176-178.
96. Liang X.B., Ma L.J., Naito T., Wang Y., Madaio M., Zent R., Pozzi A., Fogo A.B. Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J. Am. Soc. Nephrol. 2006, 17:1886-1895.
97. Liebau M.C., Lang D., Bohm J., Endlich N., Bek M.J., Witherden I., Mathieson P.W., Saleem M.A., Pavenstadt H., Fischer K.G. Functional expression of the renin-angiotensin system in human podocytes. Am. J. Physiol. 2006, 290:710-719.
98. Lin S.L., Chen R.H., Chen Y.M., Chiang W.C., Lai C.F., Wu K.D., Tsai T.J. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J. Am. Soc. Nephrol. 2005, 16:2702-2713.
99. Lin M., Yiu W.H., Wu H.J., Chan L.Y., Leung J.C., Au W.S., Chan K.W., Lai K.N., Tang S.C. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J. Am. Soc. Nephrol. 2012, 23:86-102.
100. Lloberas N., Cruzado J.M., Franquesa M., Herrero-Fresneda I., Torras J., Alperovich G., Rama I., Vidal A., Grinyo J.M. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J. Am. Soc. Nephrol. 2006, 17:1395-1404.
101. Lopez-Novoa J.M., de Arriba G., Barrio V., Rodriguez-Puyol D. Adenosine induces a calcium-dependent glomerular contraction. Eur. J. Pharmacol. 1987, 134:365-367.
102. Lu T.C., Wang Z.H., Feng X., Chuang P.Y., Fang W., Shen Y., Levy D.E., Xiong H., Chen N., He J.C. Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. Kidney Int. 2009, 76:63-71.
103. Manni M.E., Bigagli E., Lodovici M., Zazzeri M., Raimondi L. The protective effect of losartan in the nephropathy of the diabetic rat includes the control of monoamine oxidase type A activity. Pharmacol. Res. 2012, 65:465-471.
104. Marco G.S., Colucci J.A., Fernandes F.B., Vio C.P., Schor N., Casarini D.E. Diabetes induces changes of catecholamines in primary mesangial cells. Int. J. Biochem. Cell Biol. 2008, 40:747-754.
105. Mason R.M., Wahab N.A. Extracellular matrix metabolism in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14:1358-1373.
106. Matavelli L.C., Huang J., Siragy H.M. (Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation. Clin. Exp. Pharmacol. Physiol. 2010, 37:277-282.
107. Mauer S.M., Steffes M.W., Ellis E.N., Sutherland D.E., Brown D.M., Goetz F.C. Structural-functional relationships in diabetic nephropathy. J. Clin. Invest. 1984, 74:1143-1155.
108. McCormick B.B., Sydor A., Akbari A., Fergusson D., Doucette S., Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am. J. Kidney Dis. 2008, 52:454-463.
109. Meier M., Park J.K., Overheu D., Kirsch T., Lindschau C., Gueler F., Leitges M., Menne J., Haller H. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model. Diabetes 2007, 56:346-354.
110. Menne J., Park J.K., Boehne M., Elger M., Lindschau C., Kirsch T., Meier M., Gueler F., Fiebeler A., Bahlmann F.H., Leitges M., Haller H. Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. Diabetes 2004, 53:2101-2109.
111. Mora C., Navarro J.F. Inflammation and diabetic nephropathy. Curr. Diab. Rep. 2006, 6:463-468.
112. Mori H., Inoki K., Masutani K., Wakabayashi Y., Komai K., Nakagawa R., Guan K.L., Yoshimura A. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem. Biophys. Res. Commun. 2009, 384:471-475.
113. Moriwaki Y., Yamamoto T., Shibutani Y., Aoki E., Tsutsumi Z., Takahashi S., Okamura H., Koga M., Fukuchi M., Hada T. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 2003, 52:605-608.
114. Moriwaki Y., Inokuchi T., Yamamoto A., Ka T., Tsutsumi Z., Takahashi S., Yamamoto T. Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol. 2007, 44:215-218.
115. Mukhopadhyay P., Pan H., Rajesh M., Batkai S., Patel V., Harvey-White J., Mukhopadhyay B., Hasko G., Gao B., Mackie K., Pacher P. CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br. J. Pharmacol. 2010, 160:657-668.
116. Mukhopadhyay P., Rajesh M., Pan H., Patel V., Mukhopadhyay B., Batkai S., Gao B., Hasko G., Pacher P. Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic. Biol. Med. 2010, 48:457-467.
117. Nagao T., Okura T., Irita J., Jotoku M., Enomoto D., Desilva V.R., Miyoshi K., Kurata M., Matsui Y., Uede T., Higaki J. Osteopontin plays a critical role in interstitial fibrosis but not glomerular sclerosis in diabetic nephropathy. Nephron Extra 2012, 2:87-103.
118. Nakamura T., Fukui M., Ebihara I., Osada S., Nagaoka I., Tomino Y., Koide H. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993, 42:450-456.
119. Nakamura S., Nakamura I., Ma L.J., Vaughan D.E., Fogo A. Plasminogen activator inhibitor-1 (PAI-1) expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int. 2000, 58:251-259.
120. Nam S.M., Lee M.Y., Koh J.H., Park J.H., Shin J.Y., Shin Y.G., Koh S.B., Lee E.Y., Chung C.H. Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property. Diabetes Res. Clin. Pract. 2009, 83:176-182.
121. Navar L.G. The role of the kidneys in hypertension. J. Clin. Hypertens. (Greenwich) 2005, 7:542-549.
122. Navar L.G., Kobori H., Prieto-Carrasquero M.C. Intrarenal angiotensin II and hypertension. Curr. Hypertens. Rep. 2003, 5:135-143.
123. Navarro J.F., Mora C., Rivero A., Gallego E., Chahin J., Macia M., Mendez M.L., Garcia J. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am. J. Kidney Dis. 1999, 33:458-463.
124. Navarro J.F., Milena F.J., Mora C., Leon C., Claverie F., Flores C., Garcia J. Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int. Suppl. 2005, 99:98-102.
125. Navarro J.F., Mora C., Muros M., Garcia J. Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol. Dial. Transplant. 2006, 21:3428-3434.
126. Navarro-Gonzalez J.F., Mora-Fernandez C. The Role of Inflammatory Cytokines in Diabetic Nephropathy. J. Am. Soc. Nephrol. 2008, 19:433-442.
127. Niewczas M.A., Gohda T., Skupien J., Smiles A.M., Walker W.H., Rosetti F., Cullere X., Eckfeldt J.H., Doria A., Mayadas T.N., Warram J.H., Krolewski A.S. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J. Am. Soc. Nephrol. 2012, 23:507-515.
128. Ohga S., Shikata K., Yozai K., Okada S., Ogawa D., Usui H., Wada J., Shikata Y., Makino H. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am. J. Physiol. Ren. Physiol. 2007, 292:1141-1150.
129. Ohshiro Y., Ma R.C., Yasuda Y., Hiraoka-Yamamoto J., Clermont A.C., Isshiki K., Yagi K., Arikawa E., Kern T.S., King G.L. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase C beta-null mice. Diabetes 2006, 55:3112-3120.
130. Olivera A., Lamas S., Rodriguez-Puyol D., Lopez-Novoa J.M. Adenosine induces mesangial cell contraction by an A1-type receptor. Kidney Int. 1989, 35:1300-1305.
131. Ortiz A., Egido J. Is there a role for specific anti-TNF strategies in glomerular diseases?. Nephrol. Dial. Transplant. 1995, 10:309-311.
132. Park C.W., Kim H.W., Ko S.H., Chung H.W., Lim S.W., Yang C.W., Chang Y.S., Sugawara A., Guan Y., Breyer M.D. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes 2006, 55:885-893.
133. Pawelczyk T., Grden M., Rzepko R., Sakowicz M., Szutowicz A. Region-specific alterations of adenosine receptors expression level in kidney of diabetic rat. Am. J. Pathol. 2005, 167:315-325.
134. Piek E., Heldin C.H., Ten, Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J. 1999, 13:2105-2124.
135. Poczatek M.H., Hugo C., Darley-Usmar V., Murphy-Ullrich J.E. Glucose stimulation of transforming growth factor-β bioactivity in mesangial cells is mediated by thrombospondin-1. Am. J. Pathol. 2000, 157:1353-1363.
136. Poncelet A.C., de Caestecker M.P., Schnaper H.W. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells. Kidney Int. 1999, 56:1354-1365.
137. Rasmussen H., Forder J., Kojima I., Scriabine A. TPA-induced contraction of isolated rabbit vascular smooth muscle. Biochem. Biophys. Res. Commun. 1984, 122:776-784.
138. Remmuzzi G., Cattaneo D., Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J. Am. Soc. Nephrol. 2008, 19:1459-1462.
139. Ribaldo P.D., Souza D.S., Biswas S.K., Block K., Lopes-de-Faria J.M., Lopes-de-Faria J.B. Green tea (Camellia sinensis) attenuates nephropathy by downregulating Nox4 NADPH oxidase in diabetic spontaneously hypertensive rats. J. Nutr. 2009, 139:96-100.
140. Roa H., Gajardo C., Troncoso E., Fuentealba V., Escudero C., Yanez A., Sobrevia L., Pastor-Anglada M., Quezada C., San Martin R. Adenosine mediates transforming growth factor-beta 1 release in kidney glomeruli of diabetic rats. FEBS Lett. 2009, 583:3192-3198.
141. Ruiz-Ortega M., Ruperez M., Esteban V., Rodriguez-Vita J., Sanchez-Lopez E., Carvajal G., Egido J. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol. Dial. Transplant. 2006, 21:16-20.
142. Schiffer M., Schiffer L.E., Gupta A., Shaw A.S., Roberts I.S., Mundel P., Bottinger E.P. Inhibitory smads and tgf-Beta signaling in glomerular cells. J. Am. Soc. Nephrol. 2002, 13:2657-2666.
143. Sedeek M., Hebert R.L., Kennedy C.R., Burns K.D., Touyz R.M. Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. Curr. Opin. Nephrol. Hypertens. 2009, 18:122-127.
144. Sedeek M., Callera G., Montezano A., Gutsol A., Heitz F., Szyndralewiez C., Page P., Kennedy C.R., Burns K.D., Touyz R.M., Hebert R.L. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2010, 299:F1348-F1358.
145. Sekizuka K., Tomino Y., Sei C., Kurusu A., Tashiro K., Yamaguchi Y., Kodera S., Hishiki T., Shirato I., Koide H. Detection of serum IL-6 in patients with diabetic nephropathy. Nephron 1994, 68:284-285.
146. Sen U., Rodriguez W.E., Tyagi N., Kumar M., Kundu S., Tyagi S.C. Ciglitazone, a PPARγ agonist ameliorates diabetic nephropathy, in part, through homocysteine clearance. Am. J. Physiol. Endocrinol. Metab. 2008, 295:1205-1212.
147. Shiose A., Kuroda J., Tsuruya K., Hirai M., Hirakata H., Naito S., Hattori M., Sakaki Y., Sumimoto H. A novel superoxide-producing NAD(P)H oxidase in kidney. J. Biol. Chem. 2001, 276:1417-1423.
148. Sindhu R.K., Koo J.R., Roberts C.K., Vaziri N.D. Dysregulation of hepatic superoxide dismutase, catalase and glutathione peroxidase in diabetes: response to insulin and antioxidant therapies. Clin. Exp. Hypertens 2004, 26:43-53.
149. Singh R., Alavi N., Singh A.K., Leehey D.J. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999, 48:2066-2073.
150. Siragy H.M., Xue C. Local renal aldosterone production induces inflammation, and matrix formation in kidneys of diabetic rats. Exp. Physiol. 2008, 93:817-824.
151. Spielman W.S., Arend L.J. Adenosine receptors and signaling in the kidney. Hypertension 1991, 17:117-130.
152. Sugimoto H., Shikata K., Wada J., Horiuchi S., Makino H. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible oxide synthase in diabetic rat glomerli. Diabetologia 1999, 42:878-886.
153. Tabet F., Schiffrin E.L., Callera G.E., He Y., Yao G., Ostman A., Kappert K., Tonks N.K., Touyz R.M. Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. Circ. Res. 2008, 103:149-158.
154. Taira M., Toba H., Murakami M., Iga I., Serizawa R., Murata S., Kobara M., Nakata T. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur. J. Pharmacol. 2008, 589:264-271.
155. Takebayashi K., Matsumoto S., Aso Y., Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients withtype 2 diabetes complicated by diabetic nephropathy. J. Clin. Endocrinol. Metabol. 2006, 91:2214-2217.
156. Terrell T.G., Working P.K., Chow C.P., Green J.D. Pathology of recombinant human transforming growth factor-beta 1 in rats and rabbits. Int. Rev. Exp. Pathol. 1993, 34:43-67.
157. Thallas-Bonke V., Thorpe S.R., Coughlan M.T., Fukami K., Yap F.Y., Sourris K.C., Penfold S.A., Bach L.A., Cooper M.E., Forbes J.M. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008, 57:460-469.
158. Tian L., Li C., Qi J., Fu P., Yu X., Li X., Cai L. Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction. Am. J. Physiol. Endocrinol. Metab. 2008, 295:1234-1242.
159. Tojo A., Asaba K., Onozato M.L. Suppressing renal NADPH oxidase to treat diabetic nephropathy. Expert Opin. Ther. Targets 2007, 11:1011-1018.
160. Tuttle K.R., Bakris G.L., Toto R.D., McGill J.B., Hu K., Anderson P.W. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005, 28:2686-2690.
161. Valladares D., Quezada C., Montecinos P., Concha I.I., Yanez A.J., Sobrevia L., San Martin R. Adenosine A(2B) receptor mediates an increase on VEGF-A production in rat kidney glomeruli. Biochem. Biophys. Res. Commun. 2008, 366:180-185.
162. Vallon V., Muhlbauer B., Osswald H. Adenosine and kidney function. Physiol. Rev. 2006, 86:901-940.
163. Vasavada N., Agarwal R. Role of oxidative stress in diabetic nephropathy. Adv. Chronic Kidney Dis. 2005, 12:146-154.
164. Vasquez-Vivar J., Kalyanaraman B. Generation of superoxide from nitric oxide synthase. FEBS Lett. 2000, 481:305-306.
165. Vasquez-Vivar J., Kalyanaraman B., Martasek P., Hogg N., Masters B.S., Karoui H., Tordo P., Pritchard K.A.J. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:9220-9225.
166. Vassalli P. The pathophysiology of tumor necrosis factor. Annu. Rev. Immunol. 1992, 10:411-452.
167. Vidotti D.B., Casarini D.E., Cristovam P.C., Leite C.A., Schor N., Boim M.A. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am. J. Physiol. Ren. Physiol. 2004, 286:1039-1045.
168. Vitzthum H., Weiss B., Bachleitner W., Kramer B.K., Kurtz A. Gene expression of adenosine receptors along the Nephron. Kidney Int. 2004, 65:1180-1190.
169. Vogt L., Chiurchiu C., Chadha-Boreham H., Danaietash P., Dingemanse J., Hadjadj S., Krum H., Navis G., Neuhart E., Parvanova A.I., Ruggenenti P., Woittiez A.J., Zimlichman R., Remuzzi G., de Zeeuw D. PROLONG (proteinuria lowering with urotensin receptor antagonists) study group. Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy. Hypertension 2010, 55:1206-1209.
170. Wada T., Furuichi K., Sakai N., Iwata Y., Yoshimoto K., Shimizu M., Takeda S.I., Takasawa K., Yoshimura M., Kida H., Kobayashi K.I., Mukaida N., Naito T., Matsushima K., Yokoyama H. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int. 2000, 58:1492-1499.
171. Wang X., Shaw S., Amiri F., Eaton D.C., Marrero M.B. Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in TGF-beta and fibronectin synthesis in mesangial cells. Diabetes 2002, 51:3505-3509.
172. Wang W., Koka V., Lan H.Y. Transforming growth factor-beta and Smad signaling in kidney diseases. Nephrology 2005, 10:48-56.
173. Wang H., Li Y., Liu H., Liu S., Liu Q., Wang X.M., Shi Y., Duan H. Peroxynitrite mediates glomerular lesion of diabetic rat via JAK/STAT signaling pathway. J. Endocrinol. Invest. 2009, 32:844-851.
174. Whiteside C.I., Dlugosz J.A. Mesangial cell protein kinase C isozyme activation in the diabetic milieu. Am. J. Physiol. Ren. Physiol. 2002, 282:975-980.
175. Winiarska K., Malinska D., Szymanski K., Dudziak M., Bryla J. Lipoic acid ameliorates oxidative stress and renal injury in alloxan diabetic rabbits. Biochimie 2008, 90:450-459.
176. Wolf G., Schroeder R., Ziyadeh F.N., Thaiss F., Zahner G., Stahl R.A. High glucose stimulates expression of p27Kip1 in cultured mouse mesangial cells: relationship to hypertrophy. Am. J. Physiol. 1997, 273:348-356.
177. Wolf G., Schroeder R., Thaiss F., Ziyadeh F.N., Helmchen U., Stahl R.A. Glomerular expression of p27Kip1 in diabetic db/db mouse: role of hyperglycemia. Kidney Int. 1998, 53:869-879.
178. Wolf G., Schanze A., Stahl R.A., Shankland S.J., Amann K. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency. Kidney Int. 2005, 68:1583-1589.
179. Xia L., Wang H., Goldberg H.J., Munk S., Fantus I.G., Whiteside C.I. Mesangial cell NADPH oxidase upregulation in high glucose is protein kinase C dependent and required for collagen IV expression. Am. J. Physiol. Renal Physiol. 2006, 290:F345-F356.
180. Xia L., Wang H., Munk S., Frecker H., Goldberg H.J., Fantus I.G., Whiteside C.I. Reactive oxygen species, PKC-beta1, and PKC-zeta mediate high-glucose-induced vascular endothelial growth factor expression in mesangial cells. Am. J. Physiol. Endocrinol. Metab. 2007, 293:1280-1288.
181. Xue C., Siragy H.M. Local renal aldosterone system, and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 2005, 46:584-590.
182. Yamamoto T., Nakamura T., Noble N.A., Ruoslahti E., Border W.A. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1814-1818.
183. Yamamoto T., Noble N.A., Cohen A.H., Nast C.C., Hishida A., Gold L.I., Border W.A. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int. 1996, 49:461-469.
184. Yang Y., Wang J., Qin L., Shou Z., Zhao J., Wang H., Chen Y., Chen J. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am. J. Nephrol. 2007, 27:495-502.
185. Yang S., Yao B., Zhou Y., Yin H., Zhang M.Z., Harris R.C. Intrarenal dopamine modulates progressive angiotensin II-mediated renal injury. Am. J. Physiol. Ren. Physiol. 2012, 302:742-749.
186. Yao L., Wang J., Mao Y., Zhu H., Deng A., Zhu Z. Different expressions of protein kinase C-alpha, betaI and betaII in glomeruli of diabetic nephropathy patients. J. Huazhong Univ. Sci. Technology Med. Sci. 2006, 26:651-653.
187. Yi X., Xu L., Hiller S., Kim H.S., Nickeleit V., James L.R., Maeda N. Reduced expression of lipoic acid synthase accelerates diabetic nephropathy. J. Am. Soc. Nephrol. 2012, 23:103-111.
188. Yoo K.H., Thornhill B.A., Forbes M.S., Coleman C.M., Marcinko E.S., Liaw L., Chevalier R.L. Osteopontin regulates renal apoptosis and interstitial fibrosis in neonatal chronic unilateral ureteral obstruction. Kidney Int. 2006, 70:1735-1741.
189. Yoshioka K., Takemura T., Murakami K., Okada M., Hino S., Miyamoto H., Maki S. Transforming growth factor-beta protein and mRNA in glomeruli in normal and diseased human kidneys. Lab. Invest. 1993, 68:154-163.
190. Zhang H., Saha J., Byun J., Schin M.L., Lorenz M., Kennedy R.T. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolic abnormalities in the amelioration of diabetic nephropathy. Am. J. Physiol. Ren. Physiol. 2008, 295:1071-1081.
191. Zhang J., Noble N.A., Border W.A., Owens R.T., Huang Y. Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells. Am. J. Physiol. Endocrinol. Metab. 2008, 295:810-819.
192. Zhang S., Zhang Y., Wei X., Zhen J., Wang Z., Li M., Miao W., Ding H., Du P., Zhang W., He M., Yi F. Expression and regulation of a novel identified TNFAIP8 family is associated with diabetic nephropathy. Biochim. Biophys. Acta 2010, 1802:1078-1086.
193. Zhang M.Z., Yao B., Yang S., Yang H., Wang S., Fan X., Yin H., Fogo A.B., Moeckel G.W., Harris R.C. Intrarenal dopamine inhibits progression of diabetic nephropathy. Diabetes 2012, 10.2337/db12-0046.
194. Zheng F., Fornoni A., Elliot S.J., Guan Y., Breyer M.D., Striker L.J., Striker G.E. Upregulation of type I collagen by TGF-β in mesangial cells is blocked by PPAR-γ activation. Am. J. Physiol. Ren. Physiol. 2002, 282:639-648.
195. Ziyadeh F.N. The extracellular matrix in diabetic nephropathy. Am. J. Kidney Dis. 1993, 22:736-744.
196. Zugmaier G., Paik S., Wilding G., Knabbe C., Bano M., Lupu R., Deschauer B., Simpson S., Dickson R.B., Lippman M. Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. Cancer Res. 1991, 51:3590-3594.